阿尔凯默斯 ALKS 深 沪
等待开盘 07-18 09:30:00 美东时间
29.36
+0.160
+0.55%
华盛通- 最 高29.74
- 今 开29.10
- 成交量 114.70万股
- 最 低 29.10
- 昨 收 29.20
- 总市值 48.44亿
- 52周最高 36.45
- 市盈率 静 13.53
- 换手率 0.70%
- 52周最低 25.56
- 委 比 62.71%
- 总股本 1.65亿
- 历史最高 79.041
- 量 比 0.70
- 振 幅 2.19%
- 历史最低 10.311
- 每 手 1
- 风险率 2.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Expert Outlook: Alkermes Through The Eyes Of 6 Analysts
Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months...
07-16 03:01
Goldman Sachs Initiates Coverage On Alkermes with Buy Rating, Announces Price Target of $43
Goldman Sachs analyst Andrea Newkirk initiates coverage on Alkermes (NASDAQ:ALKS) with a Buy rating and announces Price Target of $43.
07-15 20:25
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS)
Companies in the Healthcare sector have received a lot of coverage today as ana...
07-15 14:40
12款小分子新药化学结构首次公开
转自：中国医药报 在前不久美国化学会（ACS）举行的2025春季会议上，12款已进入或即将进入临床试验的小分子药物的化学结构首次公开亮相，这些潜在的新药适应证...
06-19 08:18
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
06-17 21:18
UBS Upgrades Alkermes to Buy, Raises Price Target to $42
UBS analyst Ashwani Verma upgrades Alkermes (NASDAQ:ALKS) from Neutral to Buy and raises the price target from $33 to $42.
06-17 19:48
ALZA：创新制剂的先驱和集大成者
转自：中国医药报 Alejandro Zaffaroni的其他成就 ALZA是制剂技术创新领域的代表，该公司研发的产品被业界誉为标杆。尽管在ALZA之后，还...
06-12 08:42
Alkermes Highlights LYBALVI And ARISTADA Data At Key Scientific Conferences
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles –DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc
06-02 19:07
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
